These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

203 related articles for article (PubMed ID: 23092556)

  • 1. Angiotensin II type 1 receptor antagonists inhibit cell proliferation and angiogenesis in breast cancer.
    Chen X; Meng Q; Zhao Y; Liu M; Li D; Yang Y; Sun L; Sui G; Cai L; Dong X
    Cancer Lett; 2013 Jan; 328(2):318-24. PubMed ID: 23092556
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Functional expression of the angiotensin II type 1 receptor in human ovarian carcinoma cells and its blockade therapy resulting in suppression of tumor invasion, angiogenesis, and peritoneal dissemination.
    Suganuma T; Ino K; Shibata K; Kajiyama H; Nagasaka T; Mizutani S; Kikkawa F
    Clin Cancer Res; 2005 Apr; 11(7):2686-94. PubMed ID: 15814650
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Candesartan attenuates angiogenesis in hepatocellular carcinoma via downregulating AT1R/VEGF pathway.
    Fan F; Tian C; Tao L; Wu H; Liu Z; Shen C; Jiang G; Lu Y
    Biomed Pharmacother; 2016 Oct; 83():704-711. PubMed ID: 27470571
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Overexpression of angiotensin II type 1 receptor in breast cancer cells induces epithelial-mesenchymal transition and promotes tumor growth and angiogenesis.
    Oh E; Kim JY; Cho Y; An H; Lee N; Jo H; Ban C; Seo JH
    Biochim Biophys Acta; 2016 Jun; 1863(6 Pt A):1071-81. PubMed ID: 26975580
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Inhibition of the renin-angiotensin system downregulates tissue factor and vascular endothelial growth factor in human breast carcinoma cells.
    Napoleone E; Cutrone A; Cugino D; Amore C; Di Santo A; Iacoviello L; de Gaetano G; Donati MB; Lorenzet R
    Thromb Res; 2012 Jun; 129(6):736-42. PubMed ID: 22188725
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Angiotensin II type 1 receptor antagonist as an angiogenic inhibitor in prostate cancer.
    Kosaka T; Miyajima A; Takayama E; Kikuchi E; Nakashima J; Ohigashi T; Asano T; Sakamoto M; Okita H; Murai M; Hayakawa M
    Prostate; 2007 Jan; 67(1):41-9. PubMed ID: 17044086
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Antiangiogenic mechanisms of PJ-8, a novel inhibitor of vascular endothelial growth factor receptor signaling.
    Huang SW; Lien JC; Kuo SC; Huang TF
    Carcinogenesis; 2012 May; 33(5):1022-30. PubMed ID: 22436611
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Angiotensin II type 1 receptor antagonist candesartan as an angiogenic inhibitor in a xenograft model of bladder cancer.
    Kosugi M; Miyajima A; Kikuchi E; Horiguchi Y; Murai M
    Clin Cancer Res; 2006 May; 12(9):2888-93. PubMed ID: 16675585
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Antihypertensives as novel antineoplastics: angiotensin-I-converting enzyme inhibitors and angiotensin II type 1 receptor blockers in pancreatic ductal adenocarcinoma.
    Arafat HA; Gong Q; Chipitsyna G; Rizvi A; Saa CT; Yeo CJ
    J Am Coll Surg; 2007 May; 204(5):996-1005; discussion 1005-6. PubMed ID: 17481528
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Aspirin downregulates angiotensin type 1 receptor transcription implications in capillary formation from endothelial cells.
    Mitra S; Wang X; Khaidakov M; Ding Z; Ayyadevera S; Hearnsberger E; Goyal T; Mehta JL
    J Cardiovasc Pharmacol; 2012 Aug; 60(2):187-92. PubMed ID: 22561363
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Novel hexahydrocannabinol analogs as potential anti-cancer agents inhibit cell proliferation and tumor angiogenesis.
    Thapa D; Lee JS; Heo SW; Lee YR; Kang KW; Kwak MK; Choi HG; Kim JA
    Eur J Pharmacol; 2011 Jan; 650(1):64-71. PubMed ID: 20950604
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The histone deacetylase inhibitor NVP-LAQ824 inhibits angiogenesis and has a greater antitumor effect in combination with the vascular endothelial growth factor receptor tyrosine kinase inhibitor PTK787/ZK222584.
    Qian DZ; Wang X; Kachhap SK; Kato Y; Wei Y; Zhang L; Atadja P; Pili R
    Cancer Res; 2004 Sep; 64(18):6626-34. PubMed ID: 15374977
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Angiotensin II/angiotensin II type I receptor (AT1R) signaling promotes MCF-7 breast cancer cells survival via PI3-kinase/Akt pathway.
    Zhao Y; Chen X; Cai L; Yang Y; Sui G; Fu S
    J Cell Physiol; 2010 Oct; 225(1):168-73. PubMed ID: 20458733
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Impact of ER520, a candidate of selective estrogen receptor modulators, on in vitro cell growth, migration, invasion, angiogenesis and in vivo tumor xenograft of human breast cancer cells.
    Wang L; Wang Y; Du H; Jiang Y; Tang Z; Liu H; Xiang H; Xiao H
    Cancer Chemother Pharmacol; 2015 Dec; 76(6):1247-57. PubMed ID: 26464351
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Inhibition of bladder cancer cell growth and angiogenesis by co-blockage of vascular endothelial growth factor and its receptor KDR].
    Chen XL; Liu LC; Xu ZG; Li Z; Li RW; Gao RJ; Wang S; Zhang M; Guo H
    Zhonghua Zhong Liu Za Zhi; 2008 Aug; 30(8):578-82. PubMed ID: 19102933
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Calcitriol reduces thrombospondin-1 and increases vascular endothelial growth factor in breast cancer cells: implications for tumor angiogenesis.
    García-Quiroz J; Rivas-Suárez M; García-Becerra R; Barrera D; Martínez-Reza I; Ordaz-Rosado D; Santos-Martinez N; Villanueva O; Santos-Cuevas CL; Avila E; Gamboa-Domínguez A; Halhali A; Larrea F; Díaz L
    J Steroid Biochem Mol Biol; 2014 Oct; 144 Pt A():215-22. PubMed ID: 24120914
    [TBL] [Abstract][Full Text] [Related]  

  • 17. CEP-7055: a novel, orally active pan inhibitor of vascular endothelial growth factor receptor tyrosine kinases with potent antiangiogenic activity and antitumor efficacy in preclinical models.
    Ruggeri B; Singh J; Gingrich D; Angeles T; Albom M; Yang S; Chang H; Robinson C; Hunter K; Dobrzanski P; Jones-Bolin S; Pritchard S; Aimone L; Klein-Szanto A; Herbert JM; Bono F; Schaeffer P; Casellas P; Bourie B; Pili R; Isaacs J; Ator M; Hudkins R; Vaught J; Mallamo J; Dionne C
    Cancer Res; 2003 Sep; 63(18):5978-91. PubMed ID: 14522925
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Angiotensin type 1a receptor signaling-dependent induction of vascular endothelial growth factor in stroma is relevant to tumor-associated angiogenesis and tumor growth.
    Fujita M; Hayashi I; Yamashina S; Fukamizu A; Itoman M; Majima M
    Carcinogenesis; 2005 Feb; 26(2):271-9. PubMed ID: 15637093
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Barbigerone, an isoflavone, inhibits tumor angiogenesis and human non-small-cell lung cancer xenografts growth through VEGFR2 signaling pathways.
    Li X; Wang X; Ye H; Peng A; Chen L
    Cancer Chemother Pharmacol; 2012 Sep; 70(3):425-37. PubMed ID: 22814678
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Valsartan inhibits NPC cell line CNE-2 proliferation and invasion and promotes its sensitivity to radiation.
    Wang Q; Zhao W; Wu G
    Eur J Cancer Prev; 2009 Nov; 18(6):510-7. PubMed ID: 19687742
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.